Flexion Therapeutics (NSDQ:FLXN) this week touted updated, interim results from an ongoing Phase IIIb study evaluating the safety and tolerability of repeat administration of its osteoarthritis injection, Zilretta.
The company’s injectable suspension is an extended-release formulation of triamcinolone acetonide designed for patients with osteoarthritis of the knee. Top-line results from Flexion’s trial showed that 95% of the study’s 205 patients experienced clinical benefit 12 weeks after their first injection of Zilretta. 179 patients received a second dose of the drug between weeks 12 and 24, the company said.
Get the full story at our sister site, Drug Delivery Business News.
The post Flexion touts interim data from Ph3 trial of osteoarthritis injection appeared first on MassDevice.
from MassDevice https://ift.tt/2HClde5
Cap comentari:
Publica un comentari a l'entrada